Title |
Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
|
---|---|
Published in |
Journal of Hematology & Oncology, June 2016
|
DOI | 10.1186/s13045-016-0283-0 |
Pubmed ID | |
Authors |
Larysa Sanchez, Yucai Wang, David S. Siegel, Michael L. Wang |
Abstract |
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the treatment of MM. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 29% |
Unknown | 5 | 71% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 6 | 86% |
Scientists | 1 | 14% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | <1% |
Unknown | 198 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 41 | 21% |
Researcher | 25 | 13% |
Student > Ph. D. Student | 16 | 8% |
Student > Master | 16 | 8% |
Other | 12 | 6% |
Other | 27 | 14% |
Unknown | 62 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 40 | 20% |
Medicine and Dentistry | 40 | 20% |
Agricultural and Biological Sciences | 17 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 5% |
Immunology and Microbiology | 8 | 4% |
Other | 21 | 11% |
Unknown | 63 | 32% |